- call +1-201-465-4211
- email sales@mrinsights.biz
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma.
Scope of the Report:
This report studies the CAR T-Cell Therapy for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CAR T-Cell Therapy for Multiple Myeloma market by product type and applications/end industries.
The increasing number of collaborations or licensing agreements between companies and research institute, will induce the involvement of more investors in this area. Car T-cell therapy for multiple myeloma has identified that most of the pipeline molecules in multiple myeloma are currently in the pre-clinical development stage. KMA.CAR-T the drug is under development by the company HaemaLogiX. This monotherapy drug is currently in the pre-clinical stage and the company has already signed an agreement with Westmead Institute for Medical Research.
The global CAR T-Cell Therapy for Multiple Myeloma market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of CAR T-Cell Therapy for Multiple Myeloma.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monotherapy
Combination Therapy
Market Segment by Applications, can be divided into
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 CAR T-Cell Therapy for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of CAR T-Cell Therapy for Multiple Myeloma
1.2 Classification of CAR T-Cell Therapy for Multiple Myeloma by Types
1.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Comparison by Types (2017-2023)
1.2.2 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Types in 2017
1.2.3 Monotherapy
1.2.4 Combination Therapy
1.3 Global CAR T-Cell Therapy for Multiple Myeloma Market by Application
1.3.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Multiple Myeloma
1.3.3 Refractory or Relapsed Multiple Myeloma
1.4 Global CAR T-Cell Therapy for Multiple Myeloma Market by Regions
1.4.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) CAR T-Cell Therapy for Multiple Myeloma Status and Prospect (2013-2023)
1.5 Global Market Size of CAR T-Cell Therapy for Multiple Myeloma (2013-2023)
2 Manufacturers Profiles
2.1 Juno Therapeutics
2.1.1 Business Overview
2.1.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)
2.2 Kite Pharma
2.2.1 Business Overview
2.2.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)
2.4 Collectis
2.4.1 Business Overview
2.4.2 CAR T-Cell Therapy for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Revenue, Gross Margin and Market Share (2016-2017)
3 Global CAR T-Cell Therapy for Multiple Myeloma Market Competition, by Players
3.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 CAR T-Cell Therapy for Multiple Myeloma Players Market Share
3.2.2 Top 10 CAR T-Cell Therapy for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Regions
4.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
4.3 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
4.5 South America CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
5 North America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries
5.1 North America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)
5.2 USA CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
5.3 Canada CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
5.4 Mexico CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
6 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries
6.1 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)
6.2 Germany CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
6.3 UK CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
6.4 France CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
6.5 Russia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
6.6 Italy CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
7 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)
7.2 China CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
7.3 Japan CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
7.4 Korea CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
7.5 India CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
8 South America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries
8.1 South America CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)
8.2 Brazil CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
8.3 Argentina CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
8.4 Colombia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue CAR T-Cell Therapy for Multiple Myeloma by Countries
9.1 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue by Countries (2013-2018)
9.2 Saudi Arabia CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
9.3 UAE CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
9.4 Egypt CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
9.5 Nigeria CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
9.6 South Africa CAR T-Cell Therapy for Multiple Myeloma Revenue and Growth Rate (2013-2018)
10 Global CAR T-Cell Therapy for Multiple Myeloma Market Segment by Type
10.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue and Market Share by Type (2013-2018)
10.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Forecast by Type (2018-2023)
10.3 Monotherapy Revenue Growth Rate (2013-2023)
10.4 Combination Therapy Revenue Growth Rate (2013-2023)
11 Global CAR T-Cell Therapy for Multiple Myeloma Market Segment by Application
11.1 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Application (2013-2018)
11.2 CAR T-Cell Therapy for Multiple Myeloma Market Forecast by Application (2018-2023)
11.3 Multiple Myeloma Revenue Growth (2013-2018)
11.4 Refractory or Relapsed Multiple Myeloma Revenue Growth (2013-2018)
12 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Forecast (2018-2023)
12.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Forecast (2018-2023)
12.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Forecast by Regions (2018-2023)
12.3 North America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)
12.4 Europe CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)
12.6 South America CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa CAR T-Cell Therapy for Multiple Myeloma Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure CAR T-Cell Therapy for Multiple Myeloma Picture
Table Product Specifications of CAR T-Cell Therapy for Multiple Myeloma
Table Global CAR T-Cell Therapy for Multiple
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
